This notification is to inform you of point-of-sale (POS) drug utilization review (DUR) edits for opioids that will be enforced for all Commercial plans that process claims through EnvisionRxOptions ("Envision") effective April 01, 2018.

In accordance with the Centers for Disease Control and Prevention (CDC), EnvisionRxOptions focuses on patient safety by providing interventions that avoid excessive opioid dosing and dangerous drug combinations.

The below details describe each safety edit and the associated steps needed to properly evaluate and/or adjudicate opioid claims and their rejections as they may arise. Should you have any questions, please contact the Envision Customer Care Center at 1-800-361-4542.

*Please see attached for more information*